Report #2865804

Received Oct 14, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Male
Age: 66 yrs
State: NJ
Recovered: Unknown
Vaccinated: —
Onset: Jul 2, 2025
Days to onset: —
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	55TH4	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

Shingrix late second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 66-year-old male patient who received Herpes zoster (Shingrix) (batch number 47AE2, expiry date 26-SEP-2025) and (batch number 55TH4, expiry date 31-JAN-2027) for prophylaxis. Previously administered products included Shingrix (Received 1st dose of Shingrix vaccine on 09-OCT-2023). On 02-JUL-2025, the patient received the 2nd dose of Shingrix. On 02-JUL-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: Shingrix late second dose). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 29-SEP-2025 The batch number was not provided, and we are unable to contact the reporter.